An observational study in Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukemia, sponsored by University Hospital Freiburg. Recruiting at 1 site in Germany. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-04.
Sponsored by University Hospital Freiburg · Observational
The aim of the study is to improve the accuracy of diagnosis for children and adolescents with MDS by a standardized review of morphology and standardized cytogenetic and molecular analysis.
The primary objectives of the study are:
Specifically using array-CGH to evaluate the frequency of subtle chromosomal imbalances, i.e. gains and losses of defined chromosomal regions, and amplifications.
Specifically using mFISH to identify unknown chromosomal aberrations, particularly subtle translocations involving new candidate genes, and to better define chromosomal breakpoints.
The secondary objectives of the study are:
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
This study's planned enrollment of 260 is above the median of 150 across 214 observational studies indexed under Myelodysplastic Syndromes.
Browse Myelodysplastic Syndromes studies →University Hospital Freiburg is the lead sponsor of 94 studies on the registry; 18 are open to participants now.
Counted across the registry records on this site, refreshed daily.
MDS and JMML diagnosted
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To evaluate the frequency of the different subtypes of MDS in childhood and adolescence by a standardized diagnostic approach
Time frame: 5 years
To evaluate the frequency of cytogenetic and molecular abnormalities
Time frame: 5 years
To assess survival for children and adolescents with MDS and JMML
Time frame: 5 years
To evaluate relapse rate, morbidity and mortality in children with MDS and JMML treated by HSCT
Time frame: 5 years
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital Freiburg